speb/financial-data huggingface dataset:
DRTS balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 15748000.00
DRTS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 89705391.00
DRTS income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.26
DRTS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — EBIT: -13313000.00
DRTS income_statement (quarterly, 2026-03-31) — EBITDA: -13313000.00
DRTS income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2097000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 26963000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 75755000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 6737000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 6403000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 13140000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Net Debt: 1767000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Interest Income: -9637000.00
DRTS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -9637000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Net PPE: 26963000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 69352000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 85000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 85000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 462000.00
DRTS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -13313000.00
DRTS income_statement (quarterly, 2026-03-31) — Normalized Income: -22939000.00
DRTS income_statement (quarterly, 2026-03-31) — Operating Income: -13313000.00
DRTS income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
DRTS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 90176067.00
DRTS income_statement (quarterly, 2026-03-31) — Other Gand A: 2097000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Other Payable: 5529000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Other Properties: 26963000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1121000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 71783000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Payables: 9247000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 9247000.00
DRTS income_statement (quarterly, 2026-03-31) — Pretax Income: -22950000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Receivables: 1121000.00
DRTS income_statement (quarterly, 2026-03-31) — Research And Development: 10975000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 3808000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -213075000.00
DRTS income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 241000.00
DRTS income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2338000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Share Issued: 90176067.00
DRTS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 69352000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 69352000.00
DRTS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
DRTS income_statement (quarterly, 2026-03-31) — Tax Provision: -11000.00
DRTS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Assets: 108773000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 75755000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Debt: 14341000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 69352000.00
DRTS income_statement (quarterly, 2026-03-31) — Total Expenses: 13313000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 39421000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 27425000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 28973000.00
DRTS income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -13313000.00
DRTS income_statement (quarterly, 2026-03-31) — Total Other Finance Cost: 9637000.00
DRTS balance_sheet (quarterly, 2026-03-31) — Working Capital: 70900000.00
DRUG cash_flow (annual, 2021-09-30) — Asset Impairment Charge: 0.00
DRUG cash_flow (annual, 2021-09-30) — Change In Other Current Liabilities: 0.00
DRUG balance_sheet (annual, 2021-09-30) — Goodwill And Other Intangible Assets: 2000.00
DRUG income_statement (annual, 2021-09-30) — Impairment Of Capital Assets: 0.00
DRUG cash_flow (annual, 2021-09-30) — Net Other Financing Charges: -1806626.00
DRUG balance_sheet (annual, 2021-09-30) — Other Equity Interest: -33684.00
DRUG income_statement (annual, 2021-09-30) — Other Non Operating Income Expenses: -181743.00
DRUG income_statement (annual, 2021-09-30) — Special Income Charges: 0.00
DRUG income_statement (annual, 2021-09-30) — Total Other Finance Cost: 18665.00
DRUG income_statement (annual, 2022-09-30) — +Operating Expense: 14975092.00
DRUG income_statement (annual, 2022-09-30) — +Total Revenue: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Accounts Payable: 1246384.00
DRUG cash_flow (annual, 2022-09-30) — Asset Impairment Charge: 2000.00
DRUG income_statement (annual, 2022-09-30) — Basic Average Shares: 2470383.00
DRUG income_statement (annual, 2022-09-30) — Basic EPS: -6.06
DRUG cash_flow (annual, 2022-09-30) — Beginning Cash Position: 19760015.00
DRUG balance_sheet (annual, 2022-09-30) — Capital Lease Obligations: 139911.00
DRUG balance_sheet (annual, 2022-09-30) — Capital Stock: 32237844.00
DRUG balance_sheet (annual, 2022-09-30) — Cash And Cash Equivalents: 11627913.00
DRUG balance_sheet (annual, 2022-09-30) — Cash Cash Equivalents And Short Term Investments: 11627913.00
DRUG balance_sheet (annual, 2022-09-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (annual, 2022-09-30) — Cash Financial: 11541663.00
DRUG cash_flow (annual, 2022-09-30) — Cash Flow From Continuing Financing Activities: 5196190.00
DRUG cash_flow (annual, 2022-09-30) — Cash Flow From Continuing Operating Activities: -13587116.00
DRUG cash_flow (annual, 2022-09-30) — Change In Other Current Liabilities: 2173.00
DRUG cash_flow (annual, 2022-09-30) — Change In Payables And Accrued Expense: 765988.00
DRUG cash_flow (annual, 2022-09-30) — Change In Prepaid Assets: 3778.00
DRUG cash_flow (annual, 2022-09-30) — Change In Receivables: -45633.00
DRUG cash_flow (annual, 2022-09-30) — Change In Working Capital: 724133.00
DRUG cash_flow (annual, 2022-09-30) — Changes In Cash: -8390926.00
DRUG balance_sheet (annual, 2022-09-30) — Common Stock: 32237844.00
DRUG balance_sheet (annual, 2022-09-30) — Common Stock Equity: 10542512.00
DRUG cash_flow (annual, 2022-09-30) — Common Stock Issuance: 4034884.00
DRUG balance_sheet (annual, 2022-09-30) — Current Accrued Expenses: 158177.00
DRUG balance_sheet (annual, 2022-09-30) — Current Assets: 11948121.00
DRUG balance_sheet (annual, 2022-09-30) — Current Capital Lease Obligation: 67928.00
DRUG balance_sheet (annual, 2022-09-30) — Current Debt And Capital Lease Obligation: 67928.00
DRUG balance_sheet (annual, 2022-09-30) — Current Liabilities: 1472489.00
DRUG cash_flow (annual, 2022-09-30) — Depreciation: 6037.00
DRUG cash_flow (annual, 2022-09-30) — Depreciation Amortization Depletion: 6037.00
DRUG cash_flow (annual, 2022-09-30) — Depreciation And Amortization: 6037.00
DRUG income_statement (annual, 2022-09-30) — Diluted Average Shares: 2470383.00
DRUG income_statement (annual, 2022-09-30) — Diluted EPS: -6.06
DRUG income_statement (annual, 2022-09-30) — Diluted NI Availto Com Stockholders: -14964941.00
DRUG income_statement (annual, 2022-09-30) — EBIT: -14975092.00
DRUG income_statement (annual, 2022-09-30) — EBITDA: -14969055.00
DRUG cash_flow (annual, 2022-09-30) — Effect Of Exchange Rate Changes: 258824.00
DRUG cash_flow (annual, 2022-09-30) — End Cash Position: 11627913.00
DRUG cash_flow (annual, 2022-09-30) — Financing Cash Flow: 5196190.00
DRUG cash_flow (annual, 2022-09-30) — Free Cash Flow: -13587116.00
DRUG income_statement (annual, 2022-09-30) — Gain On Sale Of Security: 12151.00
DRUG balance_sheet (annual, 2022-09-30) — Gains Losses Not Affecting Retained Earnings: 2479466.00
DRUG income_statement (annual, 2022-09-30) — General And Administrative Expense: 1999211.00
DRUG balance_sheet (annual, 2022-09-30) — Goodwill And Other Intangible Assets: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Gross PPE: 138863.00
DRUG income_statement (annual, 2022-09-30) — Impairment Of Capital Assets: 2000.00
DRUG income_statement (annual, 2022-09-30) — Interest Income: 0.00
DRUG income_statement (annual, 2022-09-30) — Interest Income Non Operating: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Invested Capital: 10542512.00
DRUG cash_flow (annual, 2022-09-30) — Issuance Of Capital Stock: 4034884.00
DRUG balance_sheet (annual, 2022-09-30) — Leases: 138863.00
DRUG balance_sheet (annual, 2022-09-30) — Long Term Capital Lease Obligation: 71983.00
DRUG balance_sheet (annual, 2022-09-30) — Long Term Debt And Capital Lease Obligation: 71983.00
DRUG cash_flow (annual, 2022-09-30) — Long Term Debt Payments: -7162.00
DRUG cash_flow (annual, 2022-09-30) — Net Common Stock Issuance: 4034884.00
DRUG cash_flow (annual, 2022-09-30) — Net Foreign Currency Exchange Gain Loss: -258824.00
DRUG income_statement (annual, 2022-09-30) — Net Income: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Income Common Stockholders: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Income Continuous Operations: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Income From Continuing And Discontinued Operation: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Income From Continuing Operation Net Minority Interest: -14964941.00
DRUG cash_flow (annual, 2022-09-30) — Net Income From Continuing Operations: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Income Including Noncontrolling Interests: -14964941.00
DRUG income_statement (annual, 2022-09-30) — Net Interest Income: 0.00
DRUG cash_flow (annual, 2022-09-30) — Net Issuance Payments Of Debt: -7162.00
DRUG cash_flow (annual, 2022-09-30) — Net Long Term Debt Issuance: -7162.00
DRUG income_statement (annual, 2022-09-30) — Net Non Operating Interest Income Expense: 0.00
DRUG cash_flow (annual, 2022-09-30) — Net Other Financing Charges: -799979.00
DRUG balance_sheet (annual, 2022-09-30) — Net PPE: 138863.00
DRUG balance_sheet (annual, 2022-09-30) — Net Tangible Assets: 10542512.00
DRUG income_statement (annual, 2022-09-30) — Normalized EBITDA: -14979206.00
DRUG income_statement (annual, 2022-09-30) — Normalized Income: -14975092.00
DRUG cash_flow (annual, 2022-09-30) — Operating Cash Flow: -13587116.00
DRUG cash_flow (annual, 2022-09-30) — Operating Gains Losses: -258824.00
DRUG income_statement (annual, 2022-09-30) — Operating Income: -14975092.00
DRUG income_statement (annual, 2022-09-30) — Operating Revenue: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Ordinary Shares Number: 3518471.00
DRUG income_statement (annual, 2022-09-30) — Other Gand A: 1899773.00
DRUG income_statement (annual, 2022-09-30) — Other Income Expense: 10151.00
DRUG cash_flow (annual, 2022-09-30) — Other Non Cash Items: 29423.00
DRUG income_statement (annual, 2022-09-30) — Other Non Operating Income Expenses: -243079.00
DRUG income_statement (annual, 2022-09-30) — Other Operating Expenses: 243079.00
DRUG balance_sheet (annual, 2022-09-30) — Other Properties: 138863.00
DRUG balance_sheet (annual, 2022-09-30) — Other Receivables: 41261.00
DRUG balance_sheet (annual, 2022-09-30) — Payables: 1246384.00
DRUG balance_sheet (annual, 2022-09-30) — Payables And Accrued Expenses: 1404561.00
DRUG balance_sheet (annual, 2022-09-30) — Prepaid Assets: 164429.00
DRUG income_statement (annual, 2022-09-30) — Pretax Income: -14964941.00
DRUG cash_flow (annual, 2022-09-30) — Proceeds From Stock Option Exercised: 1968447.00
DRUG balance_sheet (annual, 2022-09-30) — Properties: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Receivables: 155779.00
DRUG income_statement (annual, 2022-09-30) — Reconciled Depreciation: 6037.00
DRUG cash_flow (annual, 2022-09-30) — Repayment Of Debt: -7162.00
DRUG income_statement (annual, 2022-09-30) — Research And Development: 12180938.00
DRUG balance_sheet (annual, 2022-09-30) — Retained Earnings: -24174798.00
DRUG income_statement (annual, 2022-09-30) — Salaries And Wages: 99438.00
DRUG income_statement (annual, 2022-09-30) — Selling And Marketing Expense: 551864.00
DRUG income_statement (annual, 2022-09-30) — Selling General And Administration: 2551075.00
DRUG balance_sheet (annual, 2022-09-30) — Share Issued: 3518471.00
DRUG income_statement (annual, 2022-09-30) — Special Income Charges: -2000.00
DRUG cash_flow (annual, 2022-09-30) — Stock Based Compensation: 875056.00
DRUG balance_sheet (annual, 2022-09-30) — Stockholders Equity: 10542512.00
DRUG balance_sheet (annual, 2022-09-30) — Tangible Book Value: 10542512.00
DRUG income_statement (annual, 2022-09-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (annual, 2022-09-30) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (annual, 2022-09-30) — Taxes Receivable: 114518.00
DRUG balance_sheet (annual, 2022-09-30) — Total Assets: 12086984.00
DRUG balance_sheet (annual, 2022-09-30) — Total Capitalization: 10542512.00
DRUG balance_sheet (annual, 2022-09-30) — Total Debt: 139911.00
DRUG balance_sheet (annual, 2022-09-30) — Total Equity Gross Minority Interest: 10542512.00
DRUG income_statement (annual, 2022-09-30) — Total Expenses: 14975092.00
DRUG balance_sheet (annual, 2022-09-30) — Total Liabilities Net Minority Interest: 1544472.00
DRUG balance_sheet (annual, 2022-09-30) — Total Non Current Assets: 138863.00
DRUG balance_sheet (annual, 2022-09-30) — Total Non Current Liabilities Net Minority Interest: 71983.00
DRUG income_statement (annual, 2022-09-30) — Total Unusual Items: 10151.00
DRUG income_statement (annual, 2022-09-30) — Total Unusual Items Excluding Goodwill: 10151.00
DRUG balance_sheet (annual, 2022-09-30) — Working Capital: 10475632.00
DRUG income_statement (annual, 2023-09-30) — +Operating Expense: 7386414.00
DRUG income_statement (annual, 2023-09-30) — +Total Revenue: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Accounts Payable: 182307.00
DRUG cash_flow (annual, 2023-09-30) — Asset Impairment Charge: 0.00
DRUG income_statement (annual, 2023-09-30) — Basic Average Shares: 3719775.00
DRUG income_statement (annual, 2023-09-30) — Basic EPS: -1.98
DRUG cash_flow (annual, 2023-09-30) — Beginning Cash Position: 11627913.00
DRUG balance_sheet (annual, 2023-09-30) — Capital Lease Obligations: 73549.00
DRUG balance_sheet (annual, 2023-09-30) — Capital Stock: 33914308.00
DRUG balance_sheet (annual, 2023-09-30) — Cash And Cash Equivalents: 6747986.00
DRUG balance_sheet (annual, 2023-09-30) — Cash Cash Equivalents And Short Term Investments: 6747986.00
DRUG balance_sheet (annual, 2023-09-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (annual, 2023-09-30) — Cash Financial: 6661736.00
DRUG cash_flow (annual, 2023-09-30) — Cash Flow From Continuing Financing Activities: 2189686.00
DRUG cash_flow (annual, 2023-09-30) — Cash Flow From Continuing Operating Activities: -7024265.00
DRUG cash_flow (annual, 2023-09-30) — Change In Payables And Accrued Expense: -1197254.00
DRUG cash_flow (annual, 2023-09-30) — Change In Prepaid Assets: 136737.00
DRUG cash_flow (annual, 2023-09-30) — Change In Receivables: 118798.00
DRUG cash_flow (annual, 2023-09-30) — Change In Working Capital: -941719.00
DRUG cash_flow (annual, 2023-09-30) — Changes In Cash: -4834579.00
DRUG balance_sheet (annual, 2023-09-30) — Common Stock: 33914308.00
DRUG balance_sheet (annual, 2023-09-30) — Common Stock Equity: 6598216.00
DRUG cash_flow (annual, 2023-09-30) — Common Stock Issuance: 1217500.00
DRUG balance_sheet (annual, 2023-09-30) — Current Accrued Expenses: 25000.00
DRUG balance_sheet (annual, 2023-09-30) — Current Assets: 6812659.00
DRUG balance_sheet (annual, 2023-09-30) — Current Capital Lease Obligation: 73549.00
DRUG balance_sheet (annual, 2023-09-30) — Current Debt And Capital Lease Obligation: 73549.00
DRUG balance_sheet (annual, 2023-09-30) — Current Liabilities: 280856.00
DRUG cash_flow (annual, 2023-09-30) — Depreciation: 72450.00
DRUG cash_flow (annual, 2023-09-30) — Depreciation Amortization Depletion: 72450.00
DRUG cash_flow (annual, 2023-09-30) — Depreciation And Amortization: 72450.00
DRUG income_statement (annual, 2023-09-30) — Diluted Average Shares: 3719775.00
DRUG income_statement (annual, 2023-09-30) — Diluted EPS: -1.98
DRUG income_statement (annual, 2023-09-30) — Diluted NI Availto Com Stockholders: -7372225.00
DRUG income_statement (annual, 2023-09-30) — EBIT: -7386414.00
DRUG income_statement (annual, 2023-09-30) — EBITDA: -7313964.00
DRUG cash_flow (annual, 2023-09-30) — Effect Of Exchange Rate Changes: -45348.00
DRUG cash_flow (annual, 2023-09-30) — End Cash Position: 6747986.00
DRUG cash_flow (annual, 2023-09-30) — Financing Cash Flow: 2189686.00
DRUG cash_flow (annual, 2023-09-30) — Free Cash Flow: -7024265.00
DRUG income_statement (annual, 2023-09-30) — Gain On Sale Of Security: 14189.00
DRUG balance_sheet (annual, 2023-09-30) — Gains Losses Not Affecting Retained Earnings: 3399097.00
DRUG income_statement (annual, 2023-09-30) — General And Administrative Expense: 2080401.00
DRUG balance_sheet (annual, 2023-09-30) — Gross PPE: 66413.00
DRUG income_statement (annual, 2023-09-30) — Impairment Of Capital Assets: 0.00
DRUG income_statement (annual, 2023-09-30) — Interest Income: 0.00
DRUG income_statement (annual, 2023-09-30) — Interest Income Non Operating: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Invested Capital: 6598216.00
DRUG cash_flow (annual, 2023-09-30) — Issuance Of Capital Stock: 1217500.00
DRUG balance_sheet (annual, 2023-09-30) — Leases: 66413.00
DRUG balance_sheet (annual, 2023-09-30) — Long Term Capital Lease Obligation: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Long Term Debt And Capital Lease Obligation: 0.00
DRUG cash_flow (annual, 2023-09-30) — Long Term Debt Payments: -86112.00
DRUG cash_flow (annual, 2023-09-30) — Net Common Stock Issuance: 1217500.00
DRUG cash_flow (annual, 2023-09-30) — Net Foreign Currency Exchange Gain Loss: 45348.00
DRUG income_statement (annual, 2023-09-30) — Net Income: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Income Common Stockholders: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Income Continuous Operations: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Income From Continuing And Discontinued Operation: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Income From Continuing Operation Net Minority Interest: -7372225.00
DRUG cash_flow (annual, 2023-09-30) — Net Income From Continuing Operations: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Income Including Noncontrolling Interests: -7372225.00
DRUG income_statement (annual, 2023-09-30) — Net Interest Income: 0.00
DRUG cash_flow (annual, 2023-09-30) — Net Issuance Payments Of Debt: -86112.00
DRUG cash_flow (annual, 2023-09-30) — Net Long Term Debt Issuance: -86112.00
DRUG income_statement (annual, 2023-09-30) — Net Non Operating Interest Income Expense: 0.00
DRUG cash_flow (annual, 2023-09-30) — Net Other Financing Charges: -26976.00
DRUG balance_sheet (annual, 2023-09-30) — Net PPE: 66413.00
DRUG balance_sheet (annual, 2023-09-30) — Net Tangible Assets: 6598216.00
DRUG income_statement (annual, 2023-09-30) — Normalized EBITDA: -7328153.00
DRUG income_statement (annual, 2023-09-30) — Normalized Income: -7386414.00
DRUG cash_flow (annual, 2023-09-30) — Operating Cash Flow: -7024265.00
DRUG cash_flow (annual, 2023-09-30) — Operating Gains Losses: 45348.00
DRUG income_statement (annual, 2023-09-30) — Operating Income: -7386414.00
DRUG income_statement (annual, 2023-09-30) — Operating Revenue: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Ordinary Shares Number: 3772072.00
DRUG balance_sheet (annual, 2023-09-30) — Other Equity Interest: 831834.00
DRUG income_statement (annual, 2023-09-30) — Other Gand A: 923878.00
DRUG income_statement (annual, 2023-09-30) — Other Income Expense: 14189.00
DRUG cash_flow (annual, 2023-09-30) — Other Non Cash Items: 19750.00
DRUG income_statement (annual, 2023-09-30) — Other Operating Expenses: 186651.00
DRUG balance_sheet (annual, 2023-09-30) — Payables: 182307.00
DRUG balance_sheet (annual, 2023-09-30) — Payables And Accrued Expenses: 207307.00
DRUG balance_sheet (annual, 2023-09-30) — Prepaid Assets: 27692.00
DRUG income_statement (annual, 2023-09-30) — Pretax Income: -7372225.00
DRUG cash_flow (annual, 2023-09-30) — Proceeds From Stock Option Exercised: 1085274.00
DRUG balance_sheet (annual, 2023-09-30) — Properties: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Receivables: 36981.00
DRUG income_statement (annual, 2023-09-30) — Reconciled Depreciation: 72450.00
DRUG cash_flow (annual, 2023-09-30) — Repayment Of Debt: -86112.00
DRUG income_statement (annual, 2023-09-30) — Research And Development: 4999944.00
DRUG balance_sheet (annual, 2023-09-30) — Retained Earnings: -31547023.00
DRUG income_statement (annual, 2023-09-30) — Salaries And Wages: 1156523.00
DRUG income_statement (annual, 2023-09-30) — Selling And Marketing Expense: 119418.00
DRUG income_statement (annual, 2023-09-30) — Selling General And Administration: 2199819.00
DRUG balance_sheet (annual, 2023-09-30) — Share Issued: 3772072.00
DRUG income_statement (annual, 2023-09-30) — Special Income Charges: 0.00
DRUG cash_flow (annual, 2023-09-30) — Stock Based Compensation: 1152131.00
DRUG balance_sheet (annual, 2023-09-30) — Stockholders Equity: 6598216.00
DRUG balance_sheet (annual, 2023-09-30) — Tangible Book Value: 6598216.00
DRUG income_statement (annual, 2023-09-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (annual, 2023-09-30) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (annual, 2023-09-30) — Taxes Receivable: 36981.00
DRUG balance_sheet (annual, 2023-09-30) — Total Assets: 6879072.00
DRUG balance_sheet (annual, 2023-09-30) — Total Capitalization: 6598216.00
DRUG balance_sheet (annual, 2023-09-30) — Total Debt: 73549.00
DRUG balance_sheet (annual, 2023-09-30) — Total Equity Gross Minority Interest: 6598216.00
DRUG income_statement (annual, 2023-09-30) — Total Expenses: 7386414.00
DRUG balance_sheet (annual, 2023-09-30) — Total Liabilities Net Minority Interest: 280856.00
DRUG balance_sheet (annual, 2023-09-30) — Total Non Current Assets: 66413.00
DRUG balance_sheet (annual, 2023-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
DRUG income_statement (annual, 2023-09-30) — Total Unusual Items: 14189.00
DRUG income_statement (annual, 2023-09-30) — Total Unusual Items Excluding Goodwill: 14189.00
DRUG balance_sheet (annual, 2023-09-30) — Working Capital: 6531803.00
DRUG income_statement (annual, 2024-09-30) — +Operating Expense: 2822767.00
DRUG income_statement (annual, 2024-09-30) — +Total Revenue: 0.00
DRUG balance_sheet (annual, 2024-09-30) — Accounts Payable: 407548.00
DRUG balance_sheet (annual, 2024-09-30) — Accrued Interest Receivable: 0.00
DRUG cash_flow (annual, 2024-09-30) — Asset Impairment Charge: 0.00
DRUG income_statement (annual, 2024-09-30) — Basic Average Shares: 4310168.00
DRUG income_statement (annual, 2024-09-30) — Basic EPS: -0.65
DRUG cash_flow (annual, 2024-09-30) — Beginning Cash Position: 6747986.00
DRUG balance_sheet (annual, 2024-09-30) — Capital Lease Obligations: 118960.00
DRUG balance_sheet (annual, 2024-09-30) — Capital Stock: 35423371.00
DRUG balance_sheet (annual, 2024-09-30) — Cash And Cash Equivalents: 5720092.00
DRUG balance_sheet (annual, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 5720092.00
DRUG balance_sheet (annual, 2024-09-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (annual, 2024-09-30) — Cash Financial: 5633842.00
DRUG cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Financing Activities: 810572.00
DRUG cash_flow (annual, 2024-09-30) — Cash Flow From Continuing Operating Activities: -1850186.00
DRUG cash_flow (annual, 2024-09-30) — Change In Payables And Accrued Expense: 241992.00
DRUG cash_flow (annual, 2024-09-30) — Change In Prepaid Assets: -188936.00
DRUG cash_flow (annual, 2024-09-30) — Change In Receivables: -13243.00
DRUG cash_flow (annual, 2024-09-30) — Change In Working Capital: 39813.00
DRUG cash_flow (annual, 2024-09-30) — Changes In Cash: -1039614.00
DRUG balance_sheet (annual, 2024-09-30) — Common Stock: 35423371.00
DRUG balance_sheet (annual, 2024-09-30) — Common Stock Equity: 5536343.00
DRUG cash_flow (annual, 2024-09-30) — Common Stock Issuance: 900000.00
DRUG balance_sheet (annual, 2024-09-30) — Current Accrued Expenses: 41751.00
DRUG balance_sheet (annual, 2024-09-30) — Current Assets: 5986944.00
DRUG balance_sheet (annual, 2024-09-30) — Current Capital Lease Obligation: 79384.00
DRUG balance_sheet (annual, 2024-09-30) — Current Debt And Capital Lease Obligation: 79384.00
DRUG balance_sheet (annual, 2024-09-30) — Current Liabilities: 528683.00
DRUG cash_flow (annual, 2024-09-30) — Depreciation: 73357.00
DRUG cash_flow (annual, 2024-09-30) — Depreciation Amortization Depletion: 73357.00
DRUG cash_flow (annual, 2024-09-30) — Depreciation And Amortization: 73357.00
DRUG income_statement (annual, 2024-09-30) — Diluted Average Shares: 4310168.00
DRUG income_statement (annual, 2024-09-30) — Diluted EPS: -0.65
DRUG income_statement (annual, 2024-09-30) — Diluted NI Availto Com Stockholders: -2801946.00
DRUG income_statement (annual, 2024-09-30) — EBIT: -2822767.00
DRUG income_statement (annual, 2024-09-30) — EBITDA: -2749410.00
DRUG cash_flow (annual, 2024-09-30) — Effect Of Exchange Rate Changes: 11720.00
DRUG cash_flow (annual, 2024-09-30) — End Cash Position: 5720092.00
DRUG cash_flow (annual, 2024-09-30) — Financing Cash Flow: 810572.00
DRUG cash_flow (annual, 2024-09-30) — Free Cash Flow: -1850186.00
DRUG income_statement (annual, 2024-09-30) — Gain On Sale Of Security: -9312.00
DRUG balance_sheet (annual, 2024-09-30) — Gains Losses Not Affecting Retained Earnings: 4006368.00
DRUG income_statement (annual, 2024-09-30) — General And Administrative Expense: 1403971.00
DRUG balance_sheet (annual, 2024-09-30) — Gross PPE: 117658.00
DRUG income_statement (annual, 2024-09-30) — Impairment Of Capital Assets: 0.00
DRUG income_statement (annual, 2024-09-30) — Interest Income: 30133.00
DRUG income_statement (annual, 2024-09-30) — Interest Income Non Operating: 30133.00
DRUG balance_sheet (annual, 2024-09-30) — Invested Capital: 5536343.00
DRUG cash_flow (annual, 2024-09-30) — Issuance Of Capital Stock: 900000.00
DRUG balance_sheet (annual, 2024-09-30) — Leases: 117658.00
DRUG balance_sheet (annual, 2024-09-30) — Long Term Capital Lease Obligation: 39576.00
DRUG balance_sheet (annual, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 39576.00
DRUG cash_flow (annual, 2024-09-30) — Long Term Debt Payments: -89730.00
DRUG cash_flow (annual, 2024-09-30) — Net Common Stock Issuance: 900000.00
DRUG cash_flow (annual, 2024-09-30) — Net Foreign Currency Exchange Gain Loss: -10126.00
DRUG income_statement (annual, 2024-09-30) — Net Income: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Income Common Stockholders: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Income Continuous Operations: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Income From Continuing And Discontinued Operation: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: -2801946.00
DRUG cash_flow (annual, 2024-09-30) — Net Income From Continuing Operations: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Income Including Noncontrolling Interests: -2801946.00
DRUG income_statement (annual, 2024-09-30) — Net Interest Income: 30133.00
DRUG cash_flow (annual, 2024-09-30) — Net Issuance Payments Of Debt: -89730.00
DRUG cash_flow (annual, 2024-09-30) — Net Long Term Debt Issuance: -89730.00
DRUG income_statement (annual, 2024-09-30) — Net Non Operating Interest Income Expense: 30133.00
DRUG balance_sheet (annual, 2024-09-30) — Net PPE: 117658.00
DRUG balance_sheet (annual, 2024-09-30) — Net Tangible Assets: 5536343.00
DRUG income_statement (annual, 2024-09-30) — Normalized EBITDA: -2740098.00
DRUG income_statement (annual, 2024-09-30) — Normalized Income: -2792634.00
DRUG cash_flow (annual, 2024-09-30) — Operating Cash Flow: -1850186.00
DRUG cash_flow (annual, 2024-09-30) — Operating Gains Losses: -10126.00
DRUG income_statement (annual, 2024-09-30) — Operating Income: -2822767.00
DRUG income_statement (annual, 2024-09-30) — Operating Revenue: 0.00
DRUG balance_sheet (annual, 2024-09-30) — Ordinary Shares Number: 4524087.00
DRUG balance_sheet (annual, 2024-09-30) — Other Equity Interest: 455573.00
DRUG balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 455573.00
DRUG income_statement (annual, 2024-09-30) — Other Gand A: 910178.00
DRUG income_statement (annual, 2024-09-30) — Other Income Expense: -9312.00
DRUG cash_flow (annual, 2024-09-30) — Other Non Cash Items: 8945.00
DRUG income_statement (annual, 2024-09-30) — Other Operating Expenses: 197186.00
DRUG balance_sheet (annual, 2024-09-30) — Payables: 407548.00
DRUG balance_sheet (annual, 2024-09-30) — Payables And Accrued Expenses: 449299.00
DRUG balance_sheet (annual, 2024-09-30) — Prepaid Assets: 216628.00
DRUG income_statement (annual, 2024-09-30) — Pretax Income: -2801946.00
DRUG cash_flow (annual, 2024-09-30) — Proceeds From Stock Option Exercised: 302.00
DRUG balance_sheet (annual, 2024-09-30) — Properties: 0.00
DRUG balance_sheet (annual, 2024-09-30) — Receivables: 50224.00
DRUG income_statement (annual, 2024-09-30) — Reconciled Depreciation: 73357.00
DRUG cash_flow (annual, 2024-09-30) — Repayment Of Debt: -89730.00
DRUG income_statement (annual, 2024-09-30) — Research And Development: 1180010.00
DRUG balance_sheet (annual, 2024-09-30) — Retained Earnings: -34348969.00
DRUG income_statement (annual, 2024-09-30) — Salaries And Wages: 493793.00
DRUG income_statement (annual, 2024-09-30) — Selling And Marketing Expense: 41600.00
DRUG income_statement (annual, 2024-09-30) — Selling General And Administration: 1445571.00
DRUG balance_sheet (annual, 2024-09-30) — Share Issued: 4524087.00
DRUG income_statement (annual, 2024-09-30) — Special Income Charges: 0.00
DRUG cash_flow (annual, 2024-09-30) — Stock Based Compensation: 839771.00
DRUG balance_sheet (annual, 2024-09-30) — Stockholders Equity: 5536343.00
DRUG balance_sheet (annual, 2024-09-30) — Tangible Book Value: 5536343.00
DRUG income_statement (annual, 2024-09-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (annual, 2024-09-30) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (annual, 2024-09-30) — Taxes Receivable: 50224.00
DRUG balance_sheet (annual, 2024-09-30) — Total Assets: 6104602.00
DRUG balance_sheet (annual, 2024-09-30) — Total Capitalization: 5536343.00
DRUG balance_sheet (annual, 2024-09-30) — Total Debt: 118960.00
DRUG balance_sheet (annual, 2024-09-30) — Total Equity Gross Minority Interest: 5536343.00
DRUG income_statement (annual, 2024-09-30) — Total Expenses: 2822767.00
DRUG balance_sheet (annual, 2024-09-30) — Total Liabilities Net Minority Interest: 568259.00
DRUG balance_sheet (annual, 2024-09-30) — Total Non Current Assets: 117658.00
DRUG balance_sheet (annual, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 39576.00
DRUG income_statement (annual, 2024-09-30) — Total Unusual Items: -9312.00
DRUG income_statement (annual, 2024-09-30) — Total Unusual Items Excluding Goodwill: -9312.00
DRUG balance_sheet (annual, 2024-09-30) — Working Capital: 5458261.00
DRUG income_statement (quarterly, 2024-12-31) — Basic Average Shares: 6165783.00
DRUG income_statement (quarterly, 2024-12-31) — Basic EPS: 0.01
DRUG income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 6641678.00
DRUG income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.01
DRUG income_statement (quarterly, 2025-03-31) — +Operating Expense: 3352081.00
DRUG income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 551216.00
DRUG balance_sheet (quarterly, 2025-03-31) — Accrued Interest Receivable: 167419.00
DRUG income_statement (quarterly, 2025-03-31) — Basic Average Shares: 7038456.00
DRUG income_statement (quarterly, 2025-03-31) — Basic EPS: -0.42
DRUG cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 57896665.00
DRUG balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 166596.00
DRUG balance_sheet (quarterly, 2025-03-31) — Capital Stock: 89894906.00
DRUG balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 55679916.00
DRUG balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 55679916.00
DRUG balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 86250.00
DRUG balance_sheet (quarterly, 2025-03-31) — Cash Financial: 55593666.00
DRUG cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 225383.00
DRUG cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -2425282.00
DRUG cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 171359.00
DRUG cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -143439.00
DRUG cash_flow (quarterly, 2025-03-31) — Change In Receivables: -166548.00
DRUG cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -138628.00
DRUG cash_flow (quarterly, 2025-03-31) — Changes In Cash: -2199899.00
DRUG balance_sheet (quarterly, 2025-03-31) — Common Stock: 89894906.00
DRUG balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 55742575.00
DRUG cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 9000.00
DRUG balance_sheet (quarterly, 2025-03-31) — Current Assets: 56314874.00
DRUG balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 77750.00
DRUG balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 77750.00
DRUG balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 637966.00
DRUG cash_flow (quarterly, 2025-03-31) — Depreciation: 22481.00
DRUG cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 22481.00
DRUG cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 22481.00
DRUG income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 7038456.00
DRUG income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.42
DRUG income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — EBIT: -3352081.00
DRUG income_statement (quarterly, 2025-03-31) — EBITDA: -3329600.00
DRUG cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -16850.00
DRUG cash_flow (quarterly, 2025-03-31) — End Cash Position: 55679916.00
DRUG cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 225383.00
DRUG cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -2425282.00
DRUG income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -107685.00
DRUG balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 3097413.00
DRUG income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 589820.00
DRUG balance_sheet (quarterly, 2025-03-31) — Gross PPE: 154513.00
DRUG income_statement (quarterly, 2025-03-31) — Interest Income: 509381.00
DRUG income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 509381.00
DRUG balance_sheet (quarterly, 2025-03-31) — Invested Capital: 55742575.00
DRUG cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Leases: 154513.00
DRUG balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 88846.00
DRUG balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 88846.00
DRUG cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -24630.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 11762.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -2950385.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -2950385.00
DRUG income_statement (quarterly, 2025-03-31) — Net Interest Income: 509381.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -24630.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -24630.00
DRUG income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 509381.00
DRUG cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Net PPE: 154513.00
DRUG balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 55742575.00
DRUG income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -3221915.00
DRUG income_statement (quarterly, 2025-03-31) — Normalized Income: -2842700.00
DRUG balance_sheet (quarterly, 2025-03-31) — Notes Receivable: 10500.00
DRUG cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -2425282.00
DRUG cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 11762.00
DRUG income_statement (quarterly, 2025-03-31) — Operating Income: -3352081.00
DRUG income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 7083239.00
DRUG income_statement (quarterly, 2025-03-31) — Other Gand A: 498735.00
DRUG income_statement (quarterly, 2025-03-31) — Other Income Expense: -107685.00
DRUG cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 13580.00
DRUG income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 112839.00
DRUG balance_sheet (quarterly, 2025-03-31) — Payables: 551216.00
DRUG balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 560216.00
DRUG balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 401389.00
DRUG income_statement (quarterly, 2025-03-31) — Pretax Income: -2950385.00
DRUG cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 250013.00
DRUG balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Receivables: 233569.00
DRUG income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 22481.00
DRUG cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -24630.00
DRUG income_statement (quarterly, 2025-03-31) — Research And Development: 2563082.00
DRUG balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -37249744.00
DRUG income_statement (quarterly, 2025-03-31) — Salaries And Wages: 91085.00
DRUG income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 86340.00
DRUG income_statement (quarterly, 2025-03-31) — Selling General And Administration: 676160.00
DRUG balance_sheet (quarterly, 2025-03-31) — Share Issued: 7083239.00
DRUG cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 615908.00
DRUG balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 55742575.00
DRUG balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 55742575.00
DRUG income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 55650.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Assets: 56469387.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 55742575.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Debt: 166596.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 55742575.00
DRUG income_statement (quarterly, 2025-03-31) — Total Expenses: 3352081.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 726812.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 154513.00
DRUG balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 88846.00
DRUG income_statement (quarterly, 2025-03-31) — Total Unusual Items: -107685.00
DRUG income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -107685.00
DRUG balance_sheet (quarterly, 2025-03-31) — Working Capital: 55676908.00
DRUG income_statement (quarterly, 2025-06-30) — +Operating Expense: 3296310.00
DRUG income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 510804.00
DRUG balance_sheet (quarterly, 2025-06-30) — Accrued Interest Receivable: 157466.00
DRUG income_statement (quarterly, 2025-06-30) — Basic Average Shares: 7083962.00
DRUG income_statement (quarterly, 2025-06-30) — Basic EPS: -0.74
DRUG cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 55679916.00
DRUG balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 141030.00
DRUG balance_sheet (quarterly, 2025-06-30) — Capital Stock: 89910125.00
DRUG balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 51387560.00
DRUG balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 51387560.00
DRUG balance_sheet (quarterly, 2025-06-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (quarterly, 2025-06-30) — Cash Financial: 51301310.00
DRUG cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -16870.00
DRUG cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -1813369.00
DRUG cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -33413.00
DRUG cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -307001.00
DRUG cash_flow (quarterly, 2025-06-30) — Change In Receivables: -39065.00
DRUG cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -379479.00
DRUG cash_flow (quarterly, 2025-06-30) — Changes In Cash: -3520805.00
DRUG balance_sheet (quarterly, 2025-06-30) — Common Stock: 89910125.00
DRUG balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 51829727.00
DRUG cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 16000.00
DRUG balance_sheet (quarterly, 2025-06-30) — Current Assets: 52368584.00
DRUG balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 78188.00
DRUG balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 78188.00
DRUG balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 604991.00
DRUG cash_flow (quarterly, 2025-06-30) — Depreciation: 15845.00
DRUG cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 15845.00
DRUG cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 15845.00
DRUG income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 7083962.00
DRUG income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.74
DRUG income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — EBIT: -3296310.00
DRUG income_statement (quarterly, 2025-06-30) — EBITDA: -3280465.00
DRUG cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -771551.00
DRUG cash_flow (quarterly, 2025-06-30) — End Cash Position: 51387560.00
DRUG cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -16870.00
DRUG cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -3503935.00
DRUG income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -2680760.00
DRUG balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 4412316.00
DRUG income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 479260.00
DRUG balance_sheet (quarterly, 2025-06-30) — Gross PPE: 128976.00
DRUG income_statement (quarterly, 2025-06-30) — Interest Income: 476231.00
DRUG income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 476231.00
DRUG balance_sheet (quarterly, 2025-06-30) — Invested Capital: 51829727.00
DRUG cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Leases: 128976.00
DRUG balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 62842.00
DRUG balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 62842.00
DRUG cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -25620.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: 2463345.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -5242970.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -5242970.00
DRUG income_statement (quarterly, 2025-06-30) — Net Interest Income: 476231.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -25620.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -25620.00
DRUG income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 476231.00
DRUG cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Net PPE: 128976.00
DRUG balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 51829727.00
DRUG income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -599705.00
DRUG income_statement (quarterly, 2025-06-30) — Normalized Income: -2562210.00
DRUG cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -3503935.00
DRUG cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 2463345.00
DRUG income_statement (quarterly, 2025-06-30) — Operating Income: -3296310.00
DRUG income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 7084639.00
DRUG income_statement (quarterly, 2025-06-30) — Other Gand A: 337503.00
DRUG income_statement (quarterly, 2025-06-30) — Other Income Expense: -2422891.00
DRUG cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -1682048.00
DRUG income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 257869.00
DRUG income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 12520.00
DRUG balance_sheet (quarterly, 2025-06-30) — Payables: 510803.00
DRUG balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 526803.00
DRUG balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 708390.00
DRUG income_statement (quarterly, 2025-06-30) — Pretax Income: -5242970.00
DRUG cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 8750.00
DRUG balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Receivables: 272634.00